Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -4791.48% is 177% below its 4-year average of -1727.87%, around the middle of its 4-year range (-9042.82%–0.00%).
8.29% below its 12-month average of -4424.76%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1909.12%.
NET PROFIT MARGIN
-4791.48%
NET PROFIT MARGIN AVG TTM
-4424.76%
NET PROFIT MARGIN AVG 3Y
-2235.93%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.29%
CURRENT VS 3Y AVG
-114.29%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 742 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Mangoceuticals, Inc.
Market Cap
$7.07M
Net Profit Margin
-4791.48%
TTM Avg
-4424.76%
3Y Avg
-2235.93%
5Y Avg
N/A
Market Cap
$7.08M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.16M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$7.18M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-19.45%
5Y Avg
-19.45%
Market Cap
$7.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.34M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.31M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
Market Cap
$7.36M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
Market Cap
$6.76M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.07M | -4791.48% | -4424.76% | -2235.93% | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| KALA BIO, Inc. (KALA)vs › | $7.16M | 0.00% | 0.00% | -287.91% | -676.70% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.18M | 0.00% | 0.00% | -19.45% | -19.45% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.61% | -82.77% | -131.16% | -372.00% |
| Longeveron Inc. (LGVN)vs › | $7.36M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | -611.47% | -627.26% | -917.71% | -6297.45% |
| Aclarion, Inc. (ACON)vs › | $6.80M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
Operating Margin
-4200.5%
Net Profit Margin
-4791.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1909.12% |
| 2026-03-31 | -5014.65% |
| 2025-12-31 | -2935.60% |
| 2025-09-30 | -9042.82% |
| 2025-06-30 | -3221.61% |
| 2025-03-31 | -4427.38% |
| 2024-12-31 | -1850.88% |
| 2024-09-30 | -1498.86% |
| 2024-06-30 | -1465.39% |
| 2024-03-31 | -1105.86% |
| 2023-12-31 | -1050.87% |
| 2023-09-30 | -733.81% |
| 2023-06-30 | -1617.16% |
| 2023-03-31 | -2542.53% |
| 2022-12-31 | -7536.13% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
